Boric Acid

Summary

Boric Acid (CHEMBL42403) is an approved small-molecule astringent (ATC S02AA03); indicated across 4 conditions including vulvovaginal candidiasis and bacterial vaginosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: S02AA03
• Indications: 4 conditions
• Clinical trials: 4
• Chemistry: 61.84 Da · BH3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL42403
Name	Boric Acid
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	7628
ChEBI	CHEBI:33118
ATC	S02AA03
Molecular formula	BH3O3
Molecular weight	61.84
InChIKey	KGBXLFKZBHKPEV-UHFFFAOYSA-N

SMILES: B(O)(O)O

IUPAC name: boric acid

Pharmacological roles (ChEBI): astringent.

Also known as: Boric acid, Boric acid (bh3o3), Boric acid (h(sub 3)bo(sub 3)), Boricum acidum, E-284, E284, INS NO.284, INS-284, Nci-c56417, NSC-81726, SID17390008, SID26752774

Patent coverage: 330,022 distinct patent families (799,629 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Prelamin-A/C, Thyrotropin receptor.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	7.35	Potency	44.7	nM	CHEMBL_ACT_3654755
TSHR	5.8	Potency	1585	nM	CHEMBL_ACT_3922152
TSHR	5.8	Potency	1585	nM	CHEMBL_ACT_4619263
TDP1	5.35	Potency	4467	nM	CHEMBL_ACT_3937033

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
vulvovaginal candidiasis	3	MONDO:0006014	EFO:0007543
bacterial vaginosis	2	MONDO:0005316	EFO:0003932
periodontitis	2	MONDO:0005076	EFO:0000649

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	1
PHASE2/PHASE3	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02860845	PHASE4	COMPLETED	Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections
NCT07109869	PHASE3	RECRUITING	Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis
NCT00799214	PHASE2/PHASE3	COMPLETED	BASIC (Boric Acid, Alternate Solution for Intravaginal Colonization) Study
NCT07295210	Not specified	COMPLETED	Boric Acid Versus 10% Povidone Iodine Solution in Treatment of Otomycosis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).